
ANI Pharma (ANIP) Stock Forecast & Price Target
ANI Pharma (ANIP) Analyst Ratings
Bulls say
ANI Pharmaceuticals Inc. has experienced robust growth in its ACTH gel market, with expectations for continued expansion through 2025, bolstered by strong performance from key products such as Cortrophin Gel and Acthar Gel. Projections for adjusted operating margins suggest an increase from 25.4% in 2024 to 29.7% by 2028, alongside anticipated operating cash flow exceeding $630 million between 2025 and 2028. The company has also raised its FY 2025 revenue estimate to $269.5 million, reflecting increased demand and positive sales trends from both newly launched generics and established products, indicating a solid outlook for sustained growth.
Bears say
ANI Pharmaceuticals has experienced a notable decline in revenue within its Brands segment during the second and third quarters of 2024, attributed primarily to adverse market conditions affecting specific product molecules. The company has indicated that its Cortrophin revenue has consistently faced pricing pressure, with first-quarter results for both 2023 and 2024 falling short of expectations by approximately 10-12%, compounded by ongoing access issues linked to decreased funding for co-pay foundations serving Medicare patients. Additionally, while there were some positive adjustments in total revenue and EBITDA for the recent quarter, the market's outlook remains cautious due to significant anticipated revenue drops of over 30% in the first quarter of 2025 driven by both seasonality and external funding challenges.
This aggregate rating is based on analysts' research of ANI Pharma and is not a guaranteed prediction by Public.com or investment advice.
ANI Pharma (ANIP) Analyst Forecast & Price Prediction
Start investing in ANI Pharma (ANIP)
Order type
Buy in
Order amount
Est. shares
0 shares